Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Bilia in conjunction with the repurchase and issuance of bonds
Mandate

Vinge advises Bilia in conjunction with the repurchase and issuance of bonds

September 29, 2020 Capital Markets and Public M&A Automotive, Mobility and Electrification

Vinge has advised Bilia in connection with an offer for the repurchase of previously issued bonds as well as an issue of new non‑secured bonds in the amount of MSEK 500.

The interest rate level for the new bond is 3m STIBOR + 170 interest points.

Vinge’s team consisted of, among others, Anders Strid, Lina André and Jacob Benzow.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026